AR067972A1 - Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer - Google Patents
Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancerInfo
- Publication number
- AR067972A1 AR067972A1 ARP080103596A ARP080103596A AR067972A1 AR 067972 A1 AR067972 A1 AR 067972A1 AR P080103596 A ARP080103596 A AR P080103596A AR P080103596 A ARP080103596 A AR P080103596A AR 067972 A1 AR067972 A1 AR 067972A1
- Authority
- AR
- Argentina
- Prior art keywords
- pal
- compositions
- variant
- pharmaceutical composition
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000005847 immunogenicity Effects 0.000 abstract 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 2
- 241000078013 Trichormus variabilis Species 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Métodos para la produccion, purificacion y uso de dichas composiciones con fines terapéuticos, incluso para el tratamiento de cáncer. Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende una variante de fenilalaninamoniacoliasa de procariontes (PAL) y un portador farmacéuticamente aceptable, en donde dicha variante PAL tiene mayor actividad convertidora de fenilalanina y/o reducida inmunogenicidad, comparada con una PAL de tipo salvaje, en donde el portador farmacéuticamente aceptable comprende un estabilizador. Reivindicacion 2: La composicion farmacéutica de la reivindicacion 1, caracterizada porque uno o más residuos de aminoácidos de dicha variante de PAL han sido sustituidos por otro residuo de aminoácido, en donde la sustitucion aumenta dicha actividad y/o reduces dicha inmunogenicidad en comparacion con la PAL tipo salvaje. Reivindicacion 3: La composicion farmacéutica de la reivindicacion 2, caracterizada porque uno o más residuos de cisteína de dicha variante de PAL ha sido sustituido con un residuo de serina. Reivindicacion 4: La composicion farmacéutica de la reivindicacion 3, caracterizada porque dicha variante de PAL en donde la variante de PAL es de Anabaena variabilis (AvPAL).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6612507P | 2007-08-17 | 2007-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067972A1 true AR067972A1 (es) | 2009-10-28 |
Family
ID=40363135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103596A AR067972A1 (es) | 2007-08-17 | 2008-08-15 | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer |
| ARP190100158A AR117389A2 (es) | 2007-08-17 | 2019-01-24 | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en métodos para tratar cáncer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100158A AR117389A2 (es) | 2007-08-17 | 2019-01-24 | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en métodos para tratar cáncer |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7537923B2 (es) |
| EP (1) | EP2175875B1 (es) |
| JP (1) | JP5584120B2 (es) |
| CN (1) | CN101803492B (es) |
| AR (2) | AR067972A1 (es) |
| AU (1) | AU2008289549B2 (es) |
| BR (2) | BR122018072594B8 (es) |
| CA (1) | CA2687028C (es) |
| CL (1) | CL2008002390A1 (es) |
| CY (1) | CY1118222T1 (es) |
| DK (1) | DK2175875T3 (es) |
| ES (1) | ES2602618T3 (es) |
| HR (1) | HRP20161474T1 (es) |
| HU (1) | HUE029510T4 (es) |
| LT (1) | LT2175875T (es) |
| MX (1) | MX2009012261A (es) |
| PE (1) | PE20090605A1 (es) |
| PL (1) | PL2175875T3 (es) |
| PT (1) | PT2175875T (es) |
| RU (2) | RU2553343C2 (es) |
| SI (1) | SI2175875T1 (es) |
| TW (1) | TWI418787B (es) |
| WO (1) | WO2009025760A2 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| US8796206B2 (en) * | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| WO2011078667A2 (en) | 2009-12-22 | 2011-06-30 | Dsm Ip Assets B.V. | Method of finding a biocatalyst having ammonia lyase activity |
| HUE039516T2 (hu) * | 2010-02-04 | 2019-01-28 | Biomarin Pharm Inc | Eljárás prokarióta fenilalanin-liáz variánsok tisztítására |
| WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
| WO2014018832A1 (en) * | 2012-07-27 | 2014-01-30 | University Of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| SI2986722T1 (sl) | 2013-04-18 | 2019-07-31 | Codexis, Inc. | Umetni polipeptidi fenilalanin amonija liaze |
| WO2015073587A2 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| ES2865825T3 (es) | 2014-04-01 | 2021-10-18 | Rubius Therapeutics Inc | Procedimientos y composiciones para inmunomodulación |
| US9605252B2 (en) | 2014-04-16 | 2017-03-28 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EP3137103B1 (en) | 2014-04-29 | 2021-10-20 | Bio-Cancer Treatment International Ltd. | Methods and compositions for modulating the immune system with arginase i |
| WO2016008886A1 (en) | 2014-07-14 | 2016-01-21 | Danmarks Tekniske Universitet | Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity |
| PL3237621T3 (pl) | 2014-12-22 | 2023-10-30 | Codexis, Inc. | Warianty ludzkiej alfa-galaktozydazy |
| EP3491008A2 (en) | 2016-07-26 | 2019-06-05 | BioMarin Pharmaceutical Inc. | Novel adeno-associated virus capsid proteins |
| IT201600086488A1 (it) * | 2016-08-22 | 2018-02-22 | St Microelectronics Srl | Dispositivo a semiconduttore e corrispondente procedimento |
| SG11201906880VA (en) * | 2017-02-13 | 2019-08-27 | Codexis Inc | Engineered phenylalanine ammonia lyase polypeptides |
| KR20210008501A (ko) | 2018-05-09 | 2021-01-22 | 바이오마린 파머수티컬 인크. | 페닐케톤뇨증을 치료하는 방법 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| EP3807409A4 (en) | 2018-06-12 | 2022-08-03 | Codexis, Inc. | MODIFIED TYROSINE AMMONIA-LYASE |
| SG11202105668PA (en) | 2018-12-14 | 2021-06-29 | Codexis Inc | Engineered tyrosine ammonia lyase |
| JP2022515742A (ja) | 2018-12-20 | 2022-02-22 | コデクシス， インコーポレイテッド | α－ガラクトシダーゼバリアント |
| EP4022049A4 (en) | 2019-08-30 | 2023-11-01 | Codexis, Inc. | MODIFIED LIPASE VARIANTS |
| JP2023507575A (ja) | 2019-12-20 | 2023-02-24 | コデクシス， インコーポレイテッド | 操作された酸性アルファ－グルコシダーゼバリアント |
| TW202144575A (zh) | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | 使用ａａｖ及治療調配物之苯酮尿症治療 |
| US11959108B2 (en) | 2020-08-28 | 2024-04-16 | Codexis, Inc. | Engineered protease variants |
| CA3191900A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered amylase variants |
| EP4341394A1 (en) | 2021-05-19 | 2024-03-27 | BioMarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects |
| CA3220735A1 (en) | 2021-05-21 | 2022-11-24 | Codexis, Inc. | Engineered methionine gamma lyase variants |
| CN115873837A (zh) * | 2022-11-18 | 2023-03-31 | 安徽盈科生物科技有限公司 | 高表达的新型的苯丙氨酸解氨酶 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US6312939B1 (en) | 1992-12-04 | 2001-11-06 | Me Medical Enzymes Ag | Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| US5212939A (en) * | 1991-12-04 | 1993-05-25 | Pratt Jr John M | Marine mooring swivel fitting |
| EP0668933B1 (en) * | 1992-11-19 | 2002-10-02 | Anticancer, Inc. | Use of methioninase as an antitumor agent in anti-methionine chemotherapy |
| DK75593D0 (es) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| GB9418092D0 (en) * | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| KR0164757B1 (ko) * | 1995-06-13 | 1999-01-15 | 김광호 | 공조장치의 살균집진장치와 그 방법 |
| AU718439B2 (en) | 1995-09-21 | 2000-04-13 | Genentech Inc. | Human growth hormone variants |
| CU22585A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) * | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) * | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) * | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) * | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| JP4812167B2 (ja) | 1999-02-12 | 2011-11-09 | モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド | 薬物輸送用マトリックス、ならびにその作成方法および使用方法 |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| EP1280924A2 (en) | 2000-04-14 | 2003-02-05 | University of South Carolina Research Foundation | Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| US6967097B2 (en) * | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| US6939941B2 (en) * | 2001-09-12 | 2005-09-06 | Toray Fine Chemicals Co., Ltd. | Preparation of polysulfide compositions |
| KR20040088538A (ko) | 2002-02-26 | 2004-10-16 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 유전 인자의 재조합 방법 |
| AU2003290780B2 (en) | 2002-11-14 | 2009-05-07 | The Scripps Research Institute | Crystalline form of fatty acid amine hydrolase (FAAH) |
| CA2580679A1 (en) | 2004-09-17 | 2006-03-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| US20090038023A1 (en) * | 2005-03-10 | 2009-02-05 | Verenium Corporation | Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| DE102006032167B4 (de) | 2006-07-12 | 2014-11-27 | Evonik Degussa Gmbh | Verfahren zur Herstellung von Triallylisocyanurat (TAIC) |
| WO2008069958A2 (en) | 2006-12-01 | 2008-06-12 | The Salk Institute For Biological Studies | Substrate switched ammonia lyases and mutases |
| US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
-
2008
- 2008-04-22 US US12/107,736 patent/US7537923B2/en active Active
- 2008-04-22 US US12/107,731 patent/US7560263B2/en active Active
- 2008-08-14 CL CL2008002390A patent/CL2008002390A1/es unknown
- 2008-08-15 LT LTEP08795357.6T patent/LT2175875T/lt unknown
- 2008-08-15 AU AU2008289549A patent/AU2008289549B2/en active Active
- 2008-08-15 SI SI200831703A patent/SI2175875T1/sl unknown
- 2008-08-15 TW TW097131325A patent/TWI418787B/zh active
- 2008-08-15 CN CN200880016488.XA patent/CN101803492B/zh active Active
- 2008-08-15 DK DK08795357.6T patent/DK2175875T3/en active
- 2008-08-15 HU HUE08795357A patent/HUE029510T4/en unknown
- 2008-08-15 PE PE2008001395A patent/PE20090605A1/es active IP Right Grant
- 2008-08-15 EP EP08795357.6A patent/EP2175875B1/en active Active
- 2008-08-15 RU RU2012134838/15A patent/RU2553343C2/ru active
- 2008-08-15 RU RU2009141987/15A patent/RU2009141987A/ru not_active Application Discontinuation
- 2008-08-15 BR BR122018072594A patent/BR122018072594B8/pt active IP Right Grant
- 2008-08-15 JP JP2010521043A patent/JP5584120B2/ja active Active
- 2008-08-15 MX MX2009012261A patent/MX2009012261A/es active IP Right Grant
- 2008-08-15 AR ARP080103596A patent/AR067972A1/es not_active Application Discontinuation
- 2008-08-15 ES ES08795357.6T patent/ES2602618T3/es active Active
- 2008-08-15 CA CA2687028A patent/CA2687028C/en active Active
- 2008-08-15 PL PL08795357T patent/PL2175875T3/pl unknown
- 2008-08-15 PT PT87953576T patent/PT2175875T/pt unknown
- 2008-08-15 BR BRPI0811589A patent/BRPI0811589B8/pt active IP Right Grant
- 2008-08-15 WO PCT/US2008/009765 patent/WO2009025760A2/en active Application Filing
-
2009
- 2009-04-09 US US12/421,557 patent/US7790433B2/en active Active
-
2010
- 2010-07-09 US US12/833,911 patent/US20100278802A1/en not_active Abandoned
-
2016
- 2016-11-08 HR HRP20161474TT patent/HRP20161474T1/hr unknown
- 2016-11-10 CY CY20161101163T patent/CY1118222T1/el unknown
-
2019
- 2019-01-24 AR ARP190100158A patent/AR117389A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067972A1 (es) | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer | |
| AR066716A1 (es) | Composiciones de fenilanina amoniaco liasa procarioticas y metodos de uso de las composiciones | |
| PE20120792A1 (es) | Variantes de peptidos natriureticos de tipo c | |
| DK1877435T3 (da) | Glucagon-lignende peptid 2 (GLP-2)-analoger | |
| PH12014500922A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| CA2782444C (en) | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof | |
| MX2009011064A (es) | Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. | |
| WO2011080102A3 (en) | Glp-1 analogues and derivatives | |
| AR094178A1 (es) | Derivados de exendina-4 funcionalizada | |
| EA201691558A1 (ru) | Удаление сериновых протеаз путем обработки тонкоизмельченным диоксидом кремния | |
| RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| MY140710A (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| MX2009012675A (es) | Tensioactivos reconstituidos que tienen propiedades mejoradas. | |
| NZ703093A (en) | Purification of iduronate-2-sulfatase | |
| ECSP10010516A (es) | Uso de variantes de igf-i pegiladas para el tratamiento de trastornos neuromusculares | |
| CY1119819T1 (el) | Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας | |
| NO20080552L (no) | GLP-1 farmasoytiske sammensetninger | |
| NZ595060A (en) | Treatment of cancer with immunostimulatory hiv tat derivative polypeptides | |
| MX2010010177A (es) | Fragmentos de beta timosina mejorada. | |
| MX2009006942A (es) | Composiciones farmaceuticas de glp-1. | |
| MY155338A (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
| UA102016C2 (ru) | Короткоцепочечные пептиды как агонисты рецептора паратиреоидного гормона (pth) | |
| BR112013000923A2 (pt) | método de tratamento de hiv ou aids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |